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Table 3. There was a good relationship between CAC positive 2 or more
vessels CAD.
None 1 vessel CAD
2 or more vessel
CAD
CAC positive 17 (18,1%) 126 (37,3%) 50 (53,2%)
CAC negative 109 (44,7%) 68 (27,9%) 67 (27,5%)
Total 126 (37,3%) 95(28,1%) 117 (34,6%)
Pearson Chi-
Square value:
33,462,
p<0,0001,
Pearson
Correlation value:
0,304, p<0,0001
Table 4. There was high burden of atherosclerosis in CAC positive patients.
Low Syntax Score
(0-22)
Intermediate S.C
(23-32)
High Syntax Score
(33)
CAC positive 67 (69,3%) 24 (25,5%) 3 (3,2%)
CAC negative 220 (91,9%) 21 (8,5%) 3 (1,2%)
Total 287 (85,4%) 45 (13,5%) 6 (1,8%)
Table 2. Sensitivity, speciﬁty, positive predictivity and negative predictivity
rates of CAC for detection of CAD.
Sensitivity Speciﬁty Positive Pre. Negative Pre.
Value of CAC
for detection
CAD
77,3% 86,5% 81,9% 44,6%
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Purpose: Ischemia-modiﬁed albumin (IMA) is a very sensitive biomarker of
myocardial ischemia before necrosis. IMA has also been found to be elevated in the
setting of oxidative stress, acidosis, hypoxia, inﬂammatory state and sodium and
calcium pump disruptions which are also involved in the pathophysiologic process of
heart failure (HF). However, data about IMA levels speciﬁcally in patients with HF are
still lacking. Dobutamine (DOB) is known to increase myocardial contractility and
oxygen consumption, and thereby may precipitate myocardial ischemia and myocyte
damage. In contrast to DOB, levosimendan (LEVO) does not increase myocardial
oxygen demand and therefore is thought to have cardio protective properties. So, we
aimed to evaluate 1-) serum IMA concentrations in acute decompensated HF and 2-)
the effects of DOB and LEVO treatments on IMA levels.
Methods: This prospective multicenter study was performed at the ﬁve independent
sites. Fifty-nine patients admitted to participating centers with clinical signs and
symptoms of NYHA III-IV acute decompensated HF and LVEF <35% were enrolled
in this study. Blood samples for IMA measurements were obtained from all patients at
baseline and 24 h after the initiation of HF therapy. 18 patients were treated with
guidelines-recommended HF therapy with oxygen, diuretic, vasodilators (control
group), 18 received an additional 24-h infusion of LEVO with a loading dose of 12
mg/kg over 10 min followed by a continuous infusion of 0.2 mg/kg/min (LEVO group)
and 23 had DOB treatment with a continuous infusion of 10 mg/kg/min for 24-h in
addition to optimal pharmacologic therapy (DOB group). A single serum specimen
was also collected from 32 apparently healthy individuals. IMA concentrations wereJACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAmeasured by albumin cobalt binding colorimetric assay and results were given as
absorbance units (AU).
Results: In patients with acute decompensated HF, mean serum concentration of IMA
was found to be signiﬁcantly higher than those of apparently healthy population
(0.8940.23 AU vs 0.3790.08 AU, p<0.0001). Overall, IMA levels signiﬁcantly
decreased after 24-h of the initiation of appropriate HF therapy (0.8940.23 AU and
0.8320.18 AU, p <0.013). Furthermore, IMA levels were also found to signiﬁcantly
decrease in control group (1.0410.28 vs 0.8840.15 AU, p<0.041), in LEVO group
(0.7710.18 vs 0.7280.18 AU, p<0.046) and also in DOB group (0.8920.18 vs
0.8200.13 AU, p<0.035).
Conclusions: This study suggested for the ﬁrst time that patients with acute
decompensated HF had elevated levels of IMA when compared to healthy controls
and appropriate HF therapy signiﬁcantly reduced serum IMA levels. The ﬁndings of
this study also demonstrated that both DOB and LEVO treatments did not increase in
IMA levels, suggesting lower potential in inducing myocardial ischemia when used in
recommended doses.
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Introduction: Rolipram is a prototypic inhibitor of phosphodiesterase 4 (PDE4)
which contributes to the regulation of cAMP levels in cardiac myocytes. Recent
studies are focused on the effects of PDE inhibitors on cardiovascular function.
Controversial results exist for the effect of PDE4 on cardiovascular system. Recent
studies have shown that PDE4 inactivation can trigger arrhythmias and lead to the
development of heart failure in mice, but contradictory ﬁndings are also present.
Aim: In the current study, our aim was to investigate the molecular effects of a PDE4
inhibitor, rolipram, on naive mice heart tissue by Fourier Transform Infrared (FTIR)
Spectroscopy. This method monitors vibration groups of different molecules present
in the biological samples so that it gives detailed information about molecular
structure of the system.
Material and Methods: For the experimental part of the study, male Balb-c mice
(totally n¼25) were divided into three groups as control, rolipram 0.1 mg/kg and
rolipram 0.05 mg/kg. Animals treated with subchronic intraperitoneal administration
of rolipram for 15 days. The mice were then sacriﬁced and the heart tissues were
collected for FTIR analysis. The isolated heart samples were studied in 4000-400 cm-1
frequency range with 4 cm-1 resolution. Subsequently, the changes in the FTIR
spectral parameters upon administration of the agents were determined and statistical
analysis was performed.
Results: In this study, both doses of rolipram caused a decrease in lipid, carbohydrate
and protein content of heart indicating breakdown of these biomolecules, which may
be attributed to high cellular activation. Alterations in protein structure were also
observed in treated groups. In addition, heart membrane lipids were more ordered and
more ﬂuid as indicated by the lower frequency and the higher bandwidth values of
CH2 asymmetric stretching, implicating an abnormally increased membrane trans-
portation. Detailed analysis of ¼CH oleﬁnic band showed that rolipram caused
a decrease in the amount of unsaturated lipids in the membrane possibly due to lipid
peroxidation. Another effect of rolipram was observed in hydrogen bonded phos-
pholipids of the membrane structures from frequency changes of the PO2 and the
C¼O modes.
Conclusion: Hence, according to the FTIR spectral parameters subchronic rolipram
treatment led to severe molecular alterations in biomolecules of heart tissue and
membranes. These molecular variations offer molecular information for the action
mechanisms of rolipram on mice heart. Consequently, the ﬁndings of the present study
may suggest that, PDE4 inhibition, could affect the heart tissue which may result in
heart dysfunction and failure.
OP-166
Serum Lectin-Like Oxidized LDL Receptor-1 Levels for the Detection and
Evaluation of the Left Ventricular Systolic Heart Failure
Feyzullah Bes¸li1, Sümeyye Güllülü1, Saim Sag1, Ebru Açıkgöz2, Mesut Keçebas¸1,
Bülent Özdemir1, Aysel Aydın Kaderli1, Tunay S¸entürk1, _Ibrahim Baran1,
Emre Sarandöl2, Ali Aydınlar1
1Department of Cardiology, Medical Faculty, Uludag University, Bursa, 2Department
of Biochemistry, Medical Faculty, Uludag University, Bursa
Background: Heart failure, increasing incidence, is a serious health problem with
signiﬁcant morbidity and mortality. Early detection of heart failure and timely treat-
ment reduces morbidity and mortality. In recent years, the most extensively studied
diagnostic test is the pro-brain natriuretic peptide (pro-BNP). In addition, many
molecules, which might be useful in the diagnosis of heart failure, have been also
studied. In recent years several studies has utilized lectin-like oxidized LDL receptor-1
(LOX-1) in acute coronary syndromes. The authors suggested that LOX-1 is involved
in apoptosis and facilitates heart failure. In this study, we aimed to evaluate theLS C73
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ventricular systolic heart failure and its relationship with serum pro-BNP.
Methods: Fifty-ﬁve patients with a diagnosis of systolic heart failure and 25 patients
without systolic heart failure were enrolled in this study. The study took place in the
department of cardiology at Uludag University School of Medicine between October
2011 and April 2012. Echocardiography was performed in all cases. Serum C-reactive
protein, pro-BNP and LOX-1 levels were studied.
Results: Serum LOX-1 and pro-BNP levels were signiﬁcantly higher in the heart
failure group and showed negative correlations with left ventricular ejection fraction.
However, there was no signiﬁcant correlation between serum LOX-1 and pro-BNP
levels. In addition, LOX-1 level in patients with ischemic cardiomyopathy was
signiﬁcantly higher than the patients with dilated cardiomyopathy. ROC analysis was
done for the studied sample of serum LOX-1, the ‘cut off’ level was determined as
1.31 ng/ml for LOX-1 giving a sensitivity of 56.3% and speciﬁcity of 96% for the
diagnosis of the systolic heart failure.
Conclusion: Our study demonstrates the utility of the serum LOX-1 levels in the
diagnosis of left ventricular systolic heart failure. LOX-1 may have an important place
in the diagnosis of heart failure, especially when the etiology is ischemic cardiomy-
opathy. Further prospective studies with larger sample sizes are needed to better
understand the exact role of LOX-1 in the diagnosis and assessment of heart failure.Table 1. The demographic and baseline clinical characteristics of the heart
failure and control groups
Heart failure group Control group p value
Age (years) 64 (22-83) 62 (50-78) 0.306
Hypertension (n, %) 30 (54.5%) 14 (56%) 1.000
Hyperlipidemia (n, %) 21 (38.2%) 14 (56%) 0.323
Smoking (n, %) 9 (16.4%) 2 (8%) 0.511
Left ventricular ejection fraction 27 (18-44) 65 (54-73) <0.001
Table 2. Laboratory data of the heart failure and control groups
Heart failure Control group value
Blood glucose (mg/dl) 91.417.2 90.912 0.882
Urea (mg/dl) 45 (21-99) 32 (19-44) <0.001
Creatinine (mg/dl) 0.9 (0.6-1.4) 0.7 (0.6-1.1) <0.001
GFR (ml/min/1.73 m2) 84 (44-148) 96 (65-144) 0.012
Sodium (mg/dl) 137 (125-144) 141(138-144) <0.001
Potassium (mg/dl) 4.30.51 4.4 0.44 0.602
Calcium (mg/dl) 9.0 (6.3-10.5) 9.5 (8.6-11.2) 0.001
Hemoglobin (g/dl) 12.71.97 14.3 0.86 <0.001
LOX-1 (ng/ml) 1.46 (0.56-4.09) 0.99 (0.58-1.7) <0.001
Pro-BNP (mg/ml) 3560 (211-20806) 97 (18-184) <0.001
CRP (mg/L) 0.8 (0.3-5.5) 0.33 (0-0.5) <0.001
GFR: Glomerular ﬁltration rate, CRP: C-reactive protein, LOX-1: Lectin like oxidized LDL
receptor-1, BNP: Brain natriuretic peptide
Table 3. Comparison of patients according to the etiology of heart failure
DCMP (n¼24) ICMP (n¼ 31) p value
Ejection fraction (%) 25 (18-44) 30 (19-44) 0.165
LOX-1 (ng/ml) 1.16 (0.56-2.84) 1.65 (0.64-4.09) 0.027
Pro-BNP (mg/ml) 2806 (211-17277) 5200 (248-20806) 0.044
CRP (mg/L) 0.52 (0.3-3.5) 1.3 (0.3-5.54) 0.058
CRP: C-reactive protein, LOX-1: Lectin like oxidized LDL receptor-1, BNP: Brain natriuretic
peptide, DCMP: dilated cardiomyopathy, ICMP: ischemic cardiomyopathy
Table 1
Age (years) 63.2  12.7
Male gender 168
EF (%) 26.5  6.4
Hypertension (%) 62.3
Diabetes mellitus (%) 28.9
Smoking (%) 17.3
Ischemic cardiomyopathy (%) 82.7
WBC (X1,000/ml) 12.6  4.9
Neutrophil (%) 79.3  13.5
Lymphocyte (%) 17.1  7.2
Neutrophil-to-lymphocyte ratio 6.5  4.7
Baseline characteristics and hematological variables
Table 2
Variables Group 1 Group 2 p
D WBC 0.5  2.2 1.1  5.1 0.216
D Neutrophil 3.3  7.8 - 1.1  7.7 0.001
D Lymphocyte -1.4  6.1 1.1  5.4 0.012
D NLR 1.1  3.7 -2.7  11.6 <0.001
Comparison of changes in hematological variables of the patients who survived (group 1) and
died (group 2)after levosimendan therapyOP-167
Utility of the Neutrophil to Lymphocyte Ratio in Predicting In-hospital Mortality
in Patients That Received Levosimendan Treatment for Acute Decompensated
Heart Failure
Abdurrahman Tasal1, Ozgur Surgit2, Ahmet Bacaksiz1, Omer Goktekin1,
Huseyin Uyarel1, Mehmet Ergelen1, Ercan Erdogan1, Seref Kul1, Osman Sonmez1,
Murat Turfan1, Sitki Kucukbuzcu1, Mehmet Akif Vatankulu1, Aylin Hatice Yamac1
1Bezmialem Vakif University, Department of Cardiology, Istanbul, 2Mehmet Akif
Ersoy Egitim Aras¸tırma Hastanesi, Kardiyoloji Klinigi, Istanbul
Aim: The aim of the study was to investigate the effect of levosimendan infusion on
hematological variables in patients with acute heart failure. Also, predictive value of
these variables over in hospital mortality evaluated.C74 JACC VMethods: Two hundred and nineteen patients (168 male, 51 female, mean age
63.212.7 years) with acute exerbation of advanced heart failure (ejection fraction
35%) were included in this study. Levosimendan was initiated as a bolus of 6 mg/kg
followed by a continuous infusion of 0,1 mg/kg/min for 24 hours. Changes of
hematological variables between admission and on third day after levosimendan
infusion were evaluated. Categorical variables were expressed as frequencies and
percentages. Continuous variables were compared using analysis of variance and
Kruskal-Wallis tests for those with normal and skewed distributions, respectively.
Chi-square tests were used to compare categorical variables. Univariate and multi-
variate Cox regression models were used to evaluate the independent association of
different hematological variables with in-hospital mortality.
Results: Table 1 demonstrated the baseline demographical and laboratory
characteristics of the patients. After levosimendan therapy, signiﬁcant decrease in
WBC and neutrophil counts and increase in lymphocyte count. As a result,
neutrophil to lymphocyte ratio (NLR) decreased. Compared to patients that
survived, in patients who died during in-hospital stay, these hematological changes
not occurred (Table 2). D NLR detected as independent predictor of in hospital
mortality when other hematological variables associated with mortality analysed in
the multivariate logistic regression analysis (R2¼0.094, p¼0.003).
Conclusion: Our study showed that levosimendan treatment is associated with
signiﬁcant changes in hematological variables in patients with acute exacerbation of
advanced heart failure. The difference between baseline and post-treatment NLR is
independent predictor of in hospital mortality.OP-168
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Introduction: Disease management programs for the treatment of patients with heart
failure (HF) have been advocated by society guidelines in order to improve patient
compliance and decrease hospitalizations. However, there are several different HF
management programs; most of them are costly and are not feasible to use in various
geographic areas. The aim of this study was to assess the efﬁcacy and feasibility of
a cardiologist lead enhanced HF education at the time of hospital discharge with a 6
month phone follow- up program in chronic HF patients.
Methods: The Hit Point trial was a multicenter; randomized, controlled trial of
enhanced HF education with a 6 month phone follow-up program (EHFP) vs routine
care (RC) in patients who carried the diagnosis of HF secondary to systolic
dysfunction, had been hospitalized for HF within six months of randomization, and
had symptoms despite optimal medical therapy. Education included information on
the adherence to treatment, symptoms recognition, diet and ﬂuid intake, weight
monitoring, activity, exercise training and when to contact cardiologist. Patients wereol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
